182 related articles for article (PubMed ID: 6982933)
1. Isolation and characterization of monoclonal mouse cytotoxic T lymphocytes with specificity for HLA-A,B or -DR alloantigens.
Engelhard VH; Benjamin C
J Immunol; 1982 Dec; 129(6):2621-9. PubMed ID: 6982933
[No Abstract] [Full Text] [Related]
2. Specificity of mouse cytotoxic T lymphocytes stimulated with either HLA-A and -B or HLA-DR antigens reconstituted into phospholipid vesicles.
Engelhard VH; Kaufman JF; Strominger JL; Burakoff SJ
J Exp Med; 1980 Aug; 152(2 Pt 2):54s-64s. PubMed ID: 6157770
[TBL] [Abstract][Full Text] [Related]
3. [The HLA histocompatibility system].
Wadgymar A
Rev Invest Clin; 1984; 36(3):287-92. PubMed ID: 6393263
[No Abstract] [Full Text] [Related]
4. Cutting edge: requirement of class I signal sequence-derived peptides for HLA-E recognition by a mouse cytotoxic T cell clone.
Martinozzi S; Pacasova R; Boulouis HJ; Ulbrecht M; Weiss EH; Sigaux F; Pla M
J Immunol; 1999 May; 162(10):5662-5. PubMed ID: 10229795
[TBL] [Abstract][Full Text] [Related]
5. Influence of HLA antigen disparity on CML reactivity.
Dohi K; Ono E; Fukuda Y; Asahara T; Yahata H; Ezaki H
Hiroshima J Med Sci; 1984 Sep; 33(3):503-6. PubMed ID: 6334675
[No Abstract] [Full Text] [Related]
6. Cross-reactions between mouse Ia and human HLA-D/DR antigens analyzed with monoclonal alloantibodies.
Pierres M; Rebouah JP; Kourilsky FM; Dosseto M; Mercier P; Mawas C; Malissen B
J Immunol; 1981 Jun; 126(6):2424-9. PubMed ID: 6785353
[TBL] [Abstract][Full Text] [Related]
7. Anti-class II antibodies, but not cytotoxic T-lymphocyte antigen 4-immunoglobulin hybrid molecules, prevent rejection of major histocompatibility complex class II-negative myeloma in T-cell receptor-transgenic mice.
Dembic Z; Hofgaard PO; Omholt H; Bogen B
Scand J Immunol; 2004; 60(1-2):143-52. PubMed ID: 15238083
[TBL] [Abstract][Full Text] [Related]
8. Cellular mechanisms that maintain neonatally-induced tolerance of class II alloantigens. Evidence that precursor cytotoxic T cells are present but silenced.
Matriano JA; Socarras S; Streilein JW
J Immunol; 1994 Aug; 153(4):1515-26. PubMed ID: 8046230
[TBL] [Abstract][Full Text] [Related]
9. Cross-reactive T cell clones from unrelated individuals reveal similarities in peptide presentation between HLA-B27 and HLA-DR2.
López D; Barber DF; Villadangos JA; López de Castro JA
J Immunol; 1993 Apr; 150(7):2675-86. PubMed ID: 7681078
[TBL] [Abstract][Full Text] [Related]
10. High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis.
Riemersma SA; Oudejans JJ; Vonk MJ; Dreef EJ; Prins FA; Jansen PM; Vermeer MH; Blok P; Kibbelaar RE; Muris JJ; Schuuring EM; Kluin PM
J Pathol; 2005 Jul; 206(3):328-36. PubMed ID: 15887291
[TBL] [Abstract][Full Text] [Related]
11. Development of autologous cytotoxic CD4+ T clones in a human model of B-cell non-Hodgkin follicular lymphoma.
Mi JQ; Manches O; Wang J; Perron P; Weisbuch S; Marche PN; Renversez JC; Bensa JC; Sotto JJ; Cahn JY; Leroux D; Bonnefoix T
Br J Haematol; 2006 Nov; 135(3):324-35. PubMed ID: 16984392
[TBL] [Abstract][Full Text] [Related]
12. Potential role of a mismatched HLA-specific CTL clone developed pre-transplant in graft rejection following cord blood transplantation.
Narimatsu H; Murata M; Terakura S; Sugimoto K; Naoe T
Biol Blood Marrow Transplant; 2008 Apr; 14(4):397-402. PubMed ID: 18342781
[TBL] [Abstract][Full Text] [Related]
13. New tools to monitor the impact of viral infection on the alloreactive T-cell repertoire.
D'Orsogna LJ; Amir AL; Zoet YM; van der Meer-Prins PM; van der Slik AR; Kester MG; Heemskerk MH; Doxiadis II; Roelen DL; Claas FH
Tissue Antigens; 2009 Oct; 74(4):290-7. PubMed ID: 19624615
[TBL] [Abstract][Full Text] [Related]
14. Typing for human alloantigens with the primed lymphocyte typing technique.
Morling N; Jakobsen BK; Platz P; Ryder LP; Svejgaard A; Thomsen M
Adv Immunol; 1982; 32():65-156. PubMed ID: 6180612
[No Abstract] [Full Text] [Related]
15. Immune response to autologous human melanoma: implication of class I and II MHC products.
Fossati G; Anichini A; Taramelli D; Balsari A; Gambacorti-Passerini C; Kirkwood JM; Parmiani G
Biochim Biophys Acta; 1986 Dec; 865(3):235-51. PubMed ID: 3539196
[No Abstract] [Full Text] [Related]
16. Intercellular exchange of class II major histocompatibility complex/peptide complexes is a conserved process that requires activation of T cells but is constitutive in other types of antigen presenting cell.
Patel DM; Mannie MD
Cell Immunol; 2001 Dec; 214(2):165-72. PubMed ID: 12088415
[TBL] [Abstract][Full Text] [Related]
17. The human HLA-DR antigens are encoded by multiple beta-chain loci.
Hurley CK; Nunez G; Winchester R; Finn OJ; Levy R; Capra JD
J Immunol; 1982 Nov; 129(5):2103-8. PubMed ID: 6811658
[TBL] [Abstract][Full Text] [Related]
18. Autoimmunity following neonatal tolerance to alloantigens: role of donor I-A and I-E molecules.
Kramar G; Schurmans S; Berney M; Izui S; del Giudice G; Lambert PH
J Autoimmun; 1995 Apr; 8(2):177-92. PubMed ID: 7612147
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo evidence for high frequency of I-Ab-reactive CD4+ T cells in HLA-DQ or HLA-DRA transgenic mice lacking endogenous MHC class I and/or class II expression.
Ishimoto T; Yamamoto K; Fukui Y; Fukuda Y; Dohi K; Sasazuki T
J Immunol; 1997 Oct; 159(8):3717-22. PubMed ID: 9378957
[TBL] [Abstract][Full Text] [Related]
20. T lymphocyte clones detecting novel supertypic HLA class II allospecificities.
Flomenberg N; Knowles RW; Williams D; Horibe K; Rosenkrantz K; Dupont B
Immunogenetics; 1985; 22(3):295-300. PubMed ID: 2412958
[No Abstract] [Full Text] [Related]
[Next] [New Search]
